Correction
2019; Wiley; Volume: 75; Issue: 1 Linguagem: Inglês
10.1111/anae.14941
ISSN1365-2044
Tópico(s)Trauma and Emergency Care Studies
ResumoAnaesthesiaVolume 75, Issue 1 p. 122-123 CorrectionFree Access Correction This article corrects the following: The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology G. Erdoes, A. Koster, M. I. Meesters, E. Ortmann, D. Bolliger, E. Baryshnikova, A. Ahmed, M. D. Lance, H. B. Ravn, M. Ranucci, C. Heymann, S. Agarwal, Volume 74Issue 12Anaesthesia pages: 1589-1600 First Published online: September 17, 2019 First published: 03 December 2019 https://doi.org/10.1111/anae.14941AboutSectionsPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL In the Guidelines by Erdoes et al., ‘The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology’ 1, the following errors were made: In the section Quality of concentrated fibrinogen, the sentence, ‘Fibrinogen concentrate is a purified, pasteurised and virus-inactivated derivative of pooled plasma available from different manufacturers and initially produced to correct congenital hypofibrinogenaemia, afibrinogenaemia or dysfibrinogenaemia (Table 1)’. Table 1. Fibrinogen concentrates on the market, including their indications and availability. Prices may differ considerably according to countries, regions and hospitals and hence costs are only approximate Trade Name Manufacturer Indications Availability Costs Haemocomplettan CSL Behring Treatment and prophylaxis of acquired and congenital fibrinogen deficiency Acquired hypofibrinogenaemia resulting from severe liver parenchymal disease and increased intravascular consumption Europe: Austria, Bulgaria, Czech Republic, Germany, Hungary, Portugal, Romania, Switzerland, Taiwan, Turkey, the Netherlands ROW: Argentina, Brazil, Iran, Israel, Kuwait 469 USD (1 g) 896 USD (2 g) Riastap CSL Behring Treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency, including afibrinogenaemia and hypofibrinogenaemia Europe: Belgium, Cyprus, Denmark, Finland, France, Germany, Great Britain, Greece, Iceland, Ireland, Italy, Luxembourg, Malta, Norway, Poland, Slovak Republic, Slovenia, Spain, Sweden ROW: Australia, Canada, Mexico, New Zealand, Puerto Rico, US 486 USD (1 g) Fibrinogen HT Benesis JBPO Treatment of bleeding in patients with congenital fibrinogen deficiency Japan n.a. FabuLaishi/FibroRAAS Shanghai RAAS Haemorrhage associated with congenital hypofibrinogenaemia, dysfibrinogenaemia or afibrinogenaemia Acquired hypofibrinogenaemia due to failure of fibrinogen synthesis in severe liver disorders and in increased intravascular consumption of fibrinogen in DIC and hyperfibrinolysis China, Japan n.a. Fibryga Octapharma Congenital fibrinogen deficiency Europe: Austria, Belgium, Czech Republic, Denmark, Finland, Germany, Hungary, Luxembourg, Norway, Poland, Slovakia, Slovenia, Sweden, UK ROW: US, Canada 524 USD (1 g) Clottafact LFB Biomedicaments Treatment and prophylaxis of bleeding in patients with congenital hypo-, dys- or afibrinogaenaemia with bleeding tendency As a complementary therapy for the treatment of uncontrolled severe bleeding in acquired hypofibrinogenaemia Europe: Switzerland, France ROW: Algeria, UAE, Kuwait, Ðebanon, Marocco, Mexico 775 USD (1.5 g) FibCLOT LFB Biomedicaments Treatment and peri-operative prophylaxis of bleeding in patients with congenital hypo- or afibrinogenaemia with bleeding tendency Austria, Belgium, Czech Republic, Denmark, Finland, Germany, Greece, Hungary, Italy, Luxembourg, Norway, Slovakia, Spain, Sweden the Netherlands, UK n.a. ROW, rest of the world; DIC, disseminated intravascular coagulation; US, United States; USD, United States Dollar; n.a., not available. The words ‘purified, pasteurised’ should be deleted so that it reads: “Fibrinogen concentrate is a virus-inactivated derivative of pooled plasma available from different manufacturers and initially produced to correct congenital hypofibrinogenaemia, afibrinogenaemia or dysfibrinogenaemia (Table 1).” In Table 1, the row ‘Clottagen…’ should be deleted. Clottafact row should be updated and a new row should be added. The correct Table 1 is as below: In the section Safety and complications of fibrinogen concentrate administration, the manufacturer for Clottafact should be amended from ‘Opopharma, Urdorf, Switzerland’ to ‘LFB Biomedicaments, France’. The online version of the paper has been updated with these corrections. The authors apologise for these errors. Reference 1Erdoes G, Koster A, Meesters MI, et al. The role of fibrinogen and fibrinogen concentrate in cardiac surgery: an international consensus statement from the Haemostasis and Transfusion Scientific Subcommittee of the European Association of Cardiothoracic Anaesthesiology. Anaesthesia 2019; 74: 1590– 600. Volume75, Issue1January 2020Pages 122-123 ReferencesRelatedInformation
Referência(s)